amgen sinks as cantor flags issues with obesity drug
Published 10 days ago • 1.4K plays • Length 4:48
Download video MP4
Download video MP3
Similar videos
-
5:05
amgen has 'a lot to prove' in the weight-loss drug category, says mizuho's jared holz
-
7:56
dr. gottlieb on amgen's new weight loss drug: expect to be on par with wegovy & mounjaro or better
-
0:59
eli lilly ceo on why food companies haven't seen a big impact on sales
-
4:31
jefferies' michael yee expects amgen's horizon therapeutics deal will go through despite ftc block
-
4:14
eli lilly ceo david ricks on glp-1 and obesity drugs
-
1:08
final trades: amgen, manhattan assoc., hyg & tlt
-
7:49
ozempic, mounjaro users talk about changes to family life after weight loss
-
3:56
the shocking transformation of the uk household diet since 1980 😲🍔 bbc
-
3:56
why eating healthy is so expensive in america
-
3:40
eli lilly's obesity drug will be a tailwind for the stock, says bmo's evan seigerman
-
4:25
people are 'scratching and clawing' for negative narrative around obesity drugs: mizuho's jared holz
-
0:38
amgen beats eps and revenue, $6.42b vs. $6.38b, raises full-year guidance
-
5:06
eli lilly and novo can 'coexist for awhile' in the weight-loss drug space, says bmo's evan seigerman
-
3:27
weight loss drugs: the battle over coverage
-
5:02
bofa’s meacham on what's next for eli lilly after fda approves obesity drug
-
0:59
eli lilly goes direct-to-consumer on weight loss drugs #shorts
-
2:55
eli lilly's experimental obesity drug could be 'revolutionary,' says jim cramer
-
6:13
obesity weight loss market will remain a duopoly between novo nordisk and eli lilly: bofa’s meacham
-
7:18
amgen cfo talks q2 earnings, obesity drug, and growth
-
3:17
bofa's geoff meacham on eli lilly on q4 results: the story has changed to diabetes and obesity
-
1:16
amgen shares soar on obesity drug progress
-
54:38
beyond dna in cancer and obesity
Clip.africa.com - Privacy-policy